NXL - Bathi operasional EBITDA nexalin.com

Nexalin Technology, Inc. (NXL) focuses on depression therapy devices, expanding its presence in the US and China. Frequency patents and FDA certifications create significant barriers to entry for competitors. Efficient component logistics ensure stable supplies to clinics. The EBITDA distribution by period demonstrates cash flow dynamics, where the value is fixed at 0.00.

The stability of chip supplies for neurostimulators via Nexalin Technology (NXL) safety stocks directly impacts the regularity of cash flows. Estimated EBITDA reflects actual operating profit before taxes, eliminating subjectivity and revealing the seasonal cyclicity of inflows, which allows investors to distinguish temporary downturns from a systemic crisis and avoid overvaluing the asset when analyzing this curve.